Lexaria Bioscience (LEXX) Q4 2024 earnings summary

Executive summary

• DehydraTECH technology enhances bioavailability of APIs, supporting lower dosing and improved tolerability across pharmaceuticals, nutraceuticals, and consumer products.

• Fiscal 2024 focused on R&D for GLP-1/GIP drugs and CBD, with multiple human and animal studies completed or underway for diabetes, weight loss, and hypertension.

• Ten new patents were granted, including first patents for epilepsy treatment, expanding the intellectual property portfolio to 46 patents globally.

• Net loss from operations decreased to $5.8 million from $6.7 million year-over-year, with revenue more than doubling to $464,278.

• Leadership transition: Richard Christopher appointed CEO on August 31, 2024, with a new CFO engaged in October 2024.

Financial highlights

• Revenue increased 105% to $464,278, driven by a 212% rise in licensing revenue, offset by declines in B2B and other revenues.

• Net loss narrowed by $903,871 to $5,808,654 for the year ended August 31, 2024.

• R&D expenses decreased 36% to $2,360,565 due to completion of prior studies and a shift in focus to new drug investigations.

• General and administrative expenses rose 26% to $3,852,021, mainly from higher legal, professional, and stock-based compensation costs.

• Cash on hand at year-end was $6.5 million, with working capital of $6.8 million, supported by $10.3 million in net proceeds from equity financings and warrant exercises.

Outlook and guidance

• Anticipates increased R&D spending in 2025, contingent on successful financing.

• Plans to advance clinical trials for DehydraTECH-enhanced GLP-1/GIP drugs and CBD for diabetes, weight loss, and hypertension.

• Expects further revenue growth from technology licensing, with larger quarterly payments from existing clients in fiscal 2025.

• Current cash reserves expected to meet operational requirements for the next twelve months.